Abstract
Background and Objective
Dalcetrapib, a cholesteryl ester transfer protein (CETP) modulator, is a thioester pro-drug that is rapidly hydrolysed to generate a pharmacologically active thiol. The thiol covalently binds to plasma proteins as mixed disulfides, extensively distributes into plasma lipoprotein fractions, and is principally cleared by metabolism, including extensive first-pass metabolism. Here we report two studies assessing the effects of hepatic and renal impairment on the pharmacokinetics of the thiol and its primary metabolites.
Methods
Adults with hepatic or renal impairment and healthy controls were recruited in two separate non-randomized, open-label studies. Eligible subjects were aged 18–70 years (hepatic impairment study) or 18–75 years (renal impairment study) with a body mass index 18–40 kg/m2. Healthy controls were matched by age, bodyweight and sex. Each participant received a single 600 mg oral dose of dalcetrapib. Plasma and urine sampling was performed up to 3–4 days post-dalcetrapib administration for analysis of the pharmacokinetics of the thiol and its primary S-methyl and S-glucuronide metabolites. In the renal impairment study, CETP activity and mass, and lipid profiles were also assessed.
Results
Twenty-eight subjects were enrolled in the hepatic impairment study (mild or moderate hepatic impairment, n = 8 in each group; controls, n = 12). Thirty-five subjects participated in the renal impairment study (mild, moderate or severe renal impairment, n = 8 in each group; controls, n = 11). In patients with moderate hepatic impairment, the area under the plasma concentration–time curve from time zero to infinity (AUC∞) for thiol exposure was increased 34 % (geometric mean ratio [GMR] 1.34, 90 % CI 1.02–1.76), compared with matched controls. Regression analysis revealed a weak inverse relationship between thiol exposure and creatinine clearance (p = 0.0137, r2 = 17.1 %). In patients with moderate or severe renal impairment, thiol exposures were 62 % (AUC∞ GMR 1.62, 90 % CI 0.81–3.27) and 81 % (AUC∞ GMR 1.81, 90 % CI 1.21–2.71) higher, respectively, than matched controls. Exposures of the S-glucuronide and S-methyl metabolites were also higher in hepatic and renal impairment groups. In the renal impairment study, CETP activity was decreased following administration of dalcetrapib, with no clear differences between groups.
Conclusion
Hepatic and renal impairment both altered dalcetrapib pharmacokinetics and increased thiol exposure, with the extent of the effect dependent on the severity of impairment. The effect of renal impairment may be linked to altered distribution of the thiol, which illustrates the importance of assessing distribution to understand the causes and consequences of altered pharmacokinetics of thiol drugs in patient populations.
Similar content being viewed by others
References
Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102(10 Suppl):1K–34K.
Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977;62(5):707–14.
Navab M, Reddym ST, Van Lenten BJ, et al. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011;8(4):222–32.
Farmer JA, Liao J. Evolving concepts of the role of high-density lipoprotein in protection from atherosclerosis. Curr Atheroscler Rep. 2011;13(2):107–14.
Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406:203–7.
Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010;51(12):3443–54.
Stein EA, Stroes ES, Steiner G, et al. Safety and tolerability of dalcetrapib. Am J Cardiol. 2009;104(1):82–91.
Stein EA, Roth EM, Rhyne JM, et al. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J. 2010;31(4):480–8.
Ballantyne CM, Miller M, Niesor EJ, et al. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am Heart J. 2012;163(3):515–21.
Schwartz GG, Olsson AG, Ballantyne CM, et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009;158(6):896–901.
Schwartz GG, Olsson AG, Abt M, et al.; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089–99.
Bentley D, Young AM, Rowell L, et al. Evidence of a drug-drug interaction linked to inhibition of ester hydrolysis by orlistat. J Cardiovasc Pharmacol. 2012;60(4):390–6.
Gross G, Tardio J, Kuhlmann O. Solubility and stability of dalcetrapib in vehicles and biological media. Int J Pharm. 2012;437(1–2):103–9.
Maugeais C, von der Mark E, Niesor EJ, et al. Plasma lipoprotein fraction distribution of the CETP modulator dalcetrapib and the relationship with pharmacodynamic effects [abstract no. P25 plus poster]. High-Density Lipoprotein Satellite Symposium; Mar 30–Apr 1 2012; Cairns.
Heinig K, Bucheli F, Kuhlmann O, et al. Determination of dalcetrapib by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2012;66:314–24.
Ranalletta M, Bierilo KK, Chen Y, et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res. 2010;51(9):2739–52.
Kuhlmann O, Heinig K. Dalcetrapib pharmacokinetics and metabolism in the cynomolgus monkey. Xenobiotica. 2011;41(5):430–6.
Derks M, Busse-Reid R, Kuhlmann O, et al. [14C]-dalcetrapib ADME following a single oral dose in healthy male subjects [abstract]. Clin Pharmacol Ther. 2010;87(1 Suppl):S9–37.
Derks M, Fowler S, Kuhlmann O. A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib. Clin Ther. 2009;31(3):586–99.
Aceves-Baldo P, Anzures-Cabrera J, Bentley D. In vivo evaluation of drug-drug interactions linked to UGT inhibition: the effect of probenecid on dalcetrapib pharmacokinetics. Int J Clin Pharmacol Ther. In Press.
Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, editor. The liver and portal hypertension. Philadelphia: W.B. Saunders; 1964. p. 50–64.
Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646–9.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
Hessheimer AJ, Forner A, Varela M, et al. Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2010;22(10):1239–44.
Targher G, Chonchol M, Pichiri I, et al. Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence? J Endocrinol Invest. 2011;34(7):544–51.
Chronic Kidney Disease Prognosis Consortium, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81.
Parikh NI, Hwang SJ, Larson MG, et al. Chronic kidney disease as a predictor of cardiovascular disease (from the Framingham Heart Study). Am J Cardiol. 2008;102(1):47–53.
Kaysen GA. Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr. 2009;19(1):73–7.
Vaziri ND. Causes of dysregulation of lipid metabolism in chronic renal failure. Semin Dial. 2009;22(6):644–51.
Vaziri ND, Navab M, Fogelman AM. HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol. 2010;6(5):287–96.
Vaziri ND, Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif. 2011;3(1–3):189–96.
Delcò F, Tchambaz L, Schlienger R, et al. Dose adjustment in patients with liver disease. Drug Saf. 2005;28:529–45.
Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–61.
Zhang Y, Zhang L, Abraham S, et al. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther. 2009;85(3):305–11.
Le Couteur DG, Fraser R, Hilmer S, et al. The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet. 2005;44(2):187–200.
Hoyumpa AM, Schenker S. Is glucuronidation truly preserved in patients with liver disease? Hepatology. 1991;13(4):786–95.
Derks M, Abt M, Mwangi A, et al. Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing. Eur J Clin Pharmacol. 2010;66(8):775–83.
Dreisbach AW, Lertora JJL. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4(8):1065–74.
Dreisbach AW. The influence of chronic renal failure on drug metabolism and transport. Clin Pharmacol Ther. 2009;86(5):553–6.
Derks M, Abt M, Parr G, et al. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin. Expert Opin Investig Drugs. 2010;19(10):1135–45.
Prakash M, Upadhya S, Prabhu R. Protein thiol oxidation and lipid peroxidation in patients with uraemia. Scand J Clin Lab Invest. 2004;64:599–604.
Berezhkovskiy LM. On the influence of protein binding on pharmacological activity of drugs. J Pharm Sci. 2010;99(4):2153–65.
Acknowledgments
The authors wish to thank B. Gujral and P. Reid for operational management of the studies. These studies were supported by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Third-party writing assistance for this manuscript was provided by Prime Healthcare Ltd and funded by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Mary Phelan, Judith Anzures-Cabrera, David J. Carlile, Lucy Rowell and Darren Bentley are employees of Roche Products Ltd, Welwyn Garden City, UK, a subsidiary of F. Hoffmann-La Roche. Olaf Kuhlmann is an employee of F. Hoffmann-La Roche Ltd, Basel, Switzerland. Gerhard Arold is an employee of Pharmaceutical Research Associates International. Richard Robson is an employee of Christchurch Clinical Studies Trust.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Phelan, M., Anzures-Cabrera, J., Carlile, D.J. et al. Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dalcetrapib. Clin Pharmacokinet 52, 255–265 (2013). https://doi.org/10.1007/s40262-013-0035-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40262-013-0035-z